The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic ...

Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

WEDNESDAY, April 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the ...

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adults and adolescents aged 12 years and older ...

The condition is linked to Type 2 inflammation, which Dupixent helps target by blocking certain immune signaling pathways. The injection is already approved for CSU in several other countries ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch.

In pooled data from all three trials, the most common adverse event (≥2%) more frequently observed in patients on Dupixent compared to placebo was injection site reactions. “CSU patients with ...